ArticlePediatric rheumatology online journal2025
Evaluation of the real-world safety of Canakinumab in the treatment of systemic juvenile idiopathic arthritis in children aged 0-16: a comprehensive analysis based on FAERS data.
Peng Xiao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.